Developing Novel Therapies
for Serious Acute and
Chronic Inflammatory,
Immunologic, and
Cardiopulmonary Diseases
CalciMedica is a clinical-stage biopharmaceutical company developing novel therapies based on CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases.
The Leader in CRAC Channel Inhibition: We are advancing a new class of therapies designed to modulate the immune response and help protect against tissue cell injury, two processes central to many serious acute and chronic diseases.
Our CRAC channel inhibitors have the
potential to address important unmet
medical needs in life-threatening
or serious conditions for which there
are no-approved therapies, such as
acute pancreatitis, or disease-modifying
treatments, such as pulmonary
arterial hypertension.
AP hospitalizations per year in the US, including approximately 170K with predicted severe disease
- Standard of care: Supportive care, including IV fluids, pain control, and nutrition
- Severe complications include pancreatic necrosis, life-threatening organ failure, and acute respiratory distress syndrome (ARDS)
- Major economic burden: >1M hospital days annually and >$3B in annual US costs
Adults with PAH in the US
- Standard of care: currently approved therapies target disease-related pathways other than Orai1 and are not curative
- PAH causes chronic elevation in pulmonary artery pressure and pulmonary vascular resistance, which can lead to right ventricular (RV) hypertrophy, RV dysfunction, RV failure, and death
Novel Small Molecule CRAC Channel Inhibitors
Auxora™, an intravenous formulation of the proprietary
CRAC channel inhibitor zegocractin, is
being developed for the treatment of multiple
acute inflammatory and immunologic illnesses.
Our other proprietary drug candidate, CM5480,
is a next-generation CRAC channel inhibitor
designed for chronic dosing to treat diseases like
pulmonary arterial hypertension.
A Leadership Team
Dedicated to Science and
Innovation.
The CalciMedica team includes scientists, physicians,
drug development experts, and entrepreneurs dedicated to
advancing CRAC channel inhibitors for serious acute and chronic
inflammatory, immunologic, and cardiopulmonary diseases.
“Our focus at CalciMedica is on developing and bringing to market a new class of therapies – CRAC channel inhibitors – to treat serious inflammatory, immunologic, and cardiopulmonary diseases. We are committed to addressing areas of high unmet need with the goal of delivering safe and effective therapies to patients whose current treatment options remain inadequate.”
